Compare VENUS REMEDIES with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PFIZER VENUS REMEDIES/
PFIZER
 
P/E (TTM) x -1.1 33.7 - View Chart
P/BV x 0.1 5.7 1.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   PFIZER
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PFIZER
Mar-18
VENUS REMEDIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1262,365 5.3%   
Low Rs611,625 3.8%   
Sales per share (Unadj.) Rs301.8430.3 70.1%  
Earnings per share (Unadj.) Rs-24.978.7 -31.6%  
Cash flow per share (Unadj.) Rs2.593.2 2.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs293.3586.5 50.0%  
Shares outstanding (eoy) m12.3445.75 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.6 6.7%   
Avg P/E ratio x-3.825.3 -14.8%  
P/CF ratio (eoy) x36.721.4 171.6%  
Price / Book Value ratio x0.33.4 9.4%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m1,15491,271 1.3%   
No. of employees `0000.92.6 35.2%   
Total wages/salary Rs m3933,143 12.5%   
Avg. sales/employee Rs Th4,026.17,484.8 53.8%   
Avg. wages/employee Rs Th425.01,195.0 35.6%   
Avg. net profit/employee Rs Th-331.81,369.1 -24.2%   
INCOME DATA
Net Sales Rs m3,72419,685 18.9%  
Other income Rs m231,143 2.0%   
Total revenues Rs m3,74720,828 18.0%   
Gross profit Rs m3955,003 7.9%  
Depreciation Rs m338663 51.1%   
Interest Rs m3544 8,435.7%   
Profit before tax Rs m-2755,479 -5.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,878 1.7%   
Profit after tax Rs m-3073,601 -8.5%  
Gross profit margin %10.625.4 41.7%  
Effective tax rate %-11.534.3 -33.5%   
Net profit margin %-8.218.3 -45.1%  
BALANCE SHEET DATA
Current assets Rs m2,63824,167 10.9%   
Current liabilities Rs m2,3059,544 24.1%   
Net working cap to sales %8.974.3 12.0%  
Current ratio x1.12.5 45.2%  
Inventory Days Days13555 245.9%  
Debtors Days Days4629 161.4%  
Net fixed assets Rs m4,8719,514 51.2%   
Share capital Rs m123458 27.0%   
"Free" reserves Rs m3,49626,375 13.3%   
Net worth Rs m3,61926,832 13.5%   
Long term debt Rs m1,37425 5,497.6%   
Total assets Rs m7,50936,900 20.3%  
Interest coverage x0.21,305.5 0.0%   
Debt to equity ratio x0.40 40,759.2%  
Sales to assets ratio x0.50.5 93.0%   
Return on assets %0.69.8 6.5%  
Return on equity %-8.513.4 -63.2%  
Return on capital %1.620.4 7.7%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m022 0.0%   
Fx outflow Rs m5171,489 34.7%   
Net fx Rs m-517-1,466 35.2%   
CASH FLOW
From Operations Rs m5143,318 15.5%  
From Investments Rs m-123-2,383 5.2%  
From Financial Activity Rs m-387-1,104 35.1%  
Net Cashflow Rs m4-169 -2.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 4.9 11.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.7 280.2%  
Shareholders   20,121 85,207 23.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 16, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - AUROBINDO PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS